Small increase in dolutegravir trough, but equivalent total dolutegravir exposure with simeprevir in HIV/HCV seronegative volunteers

BACKGROUND: Dolutegravir, an HIV integrase strand-transfer inhibitor, and simeprevir, an HCV NS3/4A PI, have the potential to interact as dolutegravir is a P-glycoprotein, uridine glucuronosyl transferase 1A1 and cytochrome P4503A substrate and simeprevir has been shown to mildly inhibit these. OBJE...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:J Antimicrob Chemother
Auteurs principaux: MacBrayne, Christine E, Castillo-Mancilla, Jose, Burton Jr, James R, MaWhinney, Samantha, Wagner, Charlotte B, Micke, Kestutis, Fey, Jordan, Huntley, Ryan T, Larson, Bayli, Bushman, Lane R, Kiser, Jennifer J
Format: Artigo
Langue:Inglês
Publié: Oxford University Press 2018
Sujets:
Original Research
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5890669/
https://ncbi.nlm.nih.gov/pubmed/29029135
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jac/dkx344
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires